By Colin Kellaher
Repligen has acquired 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology applications for $70 million in cash.
Repligen, a Waltham, Mass., life-sciences company, on Tuesday said the acquired assets include Maverick and Maven for real-time monitoring and control of critical bioprocess parameters; Rebel, an at-line cell culture media analyzer; and ZipChip, a sample separations device used in the characterization of product quality attributes.
908 Devices, a Boston-based provider of devices for chemical analysis, said it will focus on growth of its handheld device portfolio for vital health and safety applications.
The company said the divestiture bolsters its balance sheet and pulls forward its profitability timeline, adding that it now expects to achieve positive adjusted Ebitda by the fourth quarter of this year and positive cash flow in 2026.
Trading in shares of 908 Devices was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 04, 2025 07:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。